STING (Stimulator of interferon genes) can recognize cyclic dinucleotides (CDNs) in the cytoplasm and activate the innate immune response through the cGAS-STING pathway. Agonists targeting STING have garnered significant attention from researchers in various disease areas such as cancer, obesity, viral infections, liver damage, and metabolic disorders. In tumors, STING primarily functions in T cell-mediated immune processes. Activation of the cGAS-STING pathway has been shown to effectively inhibit cancer cell metastasis in diseases like colon cancer, melanoma, and telomerase deficiency. STING Reporter U937 Cell Line is a luciferase reporter cell line constructed based on the STING/TBK1/IRF3 signaling pathway. Binding of CDNs to STING leads to TBK1-mediated activation of IRF3 and production of type I interferons (IFNs). IFNs activate the JAK-STAT pathway, thereby inducing luciferase expression. Luciferase readouts reflect the activation of the signaling pathway and can be utilized for evaluating the in vitro effects of CDN-related drugs.
